David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Nature. 2011 May 5;473(7345):101-4. doi: 10.1038/nature09881. Epub 2011 Apr 6.
Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS and inactivation of the p53 pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development. Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain- and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.
尽管转移性肺癌患者的患病率很高,预后很差,但肿瘤进展和转移的机制在很大程度上仍未得到阐明。在这里,我们使用小鼠中的条件等位基因,对经常带有 KRAS 点激活突变和 p53 通路失活的人类肺腺癌进行建模。在 Kras(LSL-G12D/+);p53(flox/flox) 小鼠的肺上皮细胞中,通过慢病毒介导的致癌 Kras 的体细胞激活和 p53 的缺失,启动肺腺癌的发展。尽管肿瘤是由明确的遗传改变同步启动的,但只有一部分发生恶性转化,这表明疾病的进展需要额外的改变。病毒整合位点的鉴定使我们能够区分转移性和非转移性肿瘤,并确定区分这些肿瘤类型的基因表达改变。种间分析确定 NK2 相关同源盒转录因子 Nkx2-1(也称为 Ttf-1 或 Titf1)是恶性进展的候选抑制物。在这个小鼠模型中,Nkx2-1 的阴性是高级别低分化肿瘤的特征。来自转移性和非转移性肿瘤的细胞中的获得和丧失功能实验表明,Nkx2-1 控制肿瘤分化并限制体内转移潜力。对 Nkx2-1 调控基因的分析、在特定发育阶段的肿瘤分析以及功能互补实验表明,Nkx2-1 通过抑制胚胎受限的染色质调节因子 Hmga2 部分限制肿瘤。尽管 NKX2-1 在一部分人类肺腺癌中的局灶性扩增引起了人们对其致癌功能的关注,但我们的数据特别将 Nkx2-1 的下调与分化丧失、增强的肿瘤播种能力和增加的转移倾向联系起来。因此,Nkx2-1 在同一肿瘤类型中的致癌和抑制功能证实了其作为双重功能谱系因子的作用。